iNtODEWORLD | New ‘Seoul Office’ Launch in Gangnam
17481
single,single-post,postid-17481,single-format-standard,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode_grid_1300,qode-theme-ver-11.0,qode-theme-bridge,wpb-js-composer js-comp-ver-5.1.1,vc_responsive

New ‘Seoul Office’ Launch in Gangnam

To Focus on Investor Relations and Global Business Development

As iNtRON Biotechnology (hereafter “iNtRON”) has grown up steadily, iNtRON has opened a new Seoul Office in the center of Seoul with great accessibility to focus on global business and investor relations.

iNtRON is developing novel antibiotics for the treatment of superbugs based on state of the art bacteriophage and endolysin technologies. iNtRON has conducted the world’s first clinical trial of an endolysin-based drug, which could be a potentially blockbuster and moralbuster. In addition, iNtRON aims for the global new biologics developing company with its rich pipelines including MDR TB, anticancer, botulinum toxin alternatives, ARS treatment, and etc…

iNtRON will use the Seoul Office to share its R&D progress with shareholders and investors more efficiently to maximize the value of the corporation.

 

Seoul Office Address: 419, Teheran-ro, Gangnam-gu, Seoul, Korea 06160 (Finance Plaza 14th floor)

it is iNtRON. 



iNtODEWORLD, Inc is the US subsidiary of iNtRON Biotechnology, Inc.
PGlmcmFtZSB3aWR0aD0iNzAwIiBoZWlnaHQ9IjM5NCIgc3JjPSJodHRwczovL3d3dy55b3V0dWJlLmNvbS9lbWJlZC81UDMxdTh6emF6az9yZWw9MCIgZnJhbWVib3JkZXI9IjAiIGFsbG93PSJhdXRvcGxheTsgZW5jcnlwdGVkLW1lZGlhIiBhbGxvd2Z1bGxzY3JlZW4+PC9pZnJhbWU+